Navigation Links
Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
Date:7/12/2011

SAN DIEGO, July 12, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today results from a Phase 1 clinical trial of APD811, an orally bioavailable agonist of the prostacyclin receptor which is intended for the treatment of pulmonary arterial hypertension, or PAH.

The randomized, double-blind and placebo-controlled trial evaluated the safety, tolerability and pharmacokinetics of 0.03 mg, 0.05 mg, 0.1 mg and 0.2 mg single doses of APD811. The trial evaluated 32 healthy volunteers in four cohorts of eight participants each – six randomized to APD811 and two to placebo. APD811 was rapidly absorbed and demonstrated dose-proportional pharmacokinetic exposure over the tested dose range. The terminal half-life was approximately 20 hours.

The most frequent treatment-emergent adverse events were headache, vomiting, nausea, jaw pain and flushing. Dose-limiting adverse events of nausea and vomiting occurred at the 0.2 mg dose. As compared to placebo, heart rate trended higher at the 0.05 mg, 0.1 mg and 0.2 mg doses and the corrected QT (QTc) interval trended higher at the 0.1 mg and 0.2 mg doses. Arena believes the QTc observation is not supported by preclinical data and will further evaluate this in future studies. No serious adverse events were reported.

"We are encouraged by the results of this early stage clinical trial that suggest APD811 has the potential for once-daily, oral dosing, and our next step will be to evaluate the safety, tolerability and pharmacokinetics of multiple dosing and the optimal titration schedule in a Phase 1b trial," said William R. Shanahan, M.D., Arena's Senior Vice President and Chief Medical Officer. "The development of APD811 is the result of Arena's continuing commitment to advance our diverse research and development pipeline."

About Pulmonary Arterial Hypertension (PAH)PAH is a progressi
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals Lorcaserin Achieved Statistically Significant Weight Loss
2. Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments
3. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
4. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10
5. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results and Reviews Recent Developments
6. Arena Pharmaceuticals Expands GPR119 Patent Portfolio for Type 2 Diabetes
7. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 11
8. Arena Pharmaceuticals Announces Upcoming Departure of Chief Financial Officer
9. Arena Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
10. Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application
11. Arena Pharmaceuticals to Host Conference Call and Webcast to Provide Update Following Lorcaserin End-of-Review Meeting With FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Ala. , Jan. 23, 2015 Gem Pharmaceuticals ... patients have been enrolled into the Company,s Phase 2 ... and safety of Gem,s lead compound, GPX-150 (an investigational ... advanced or metastatic disease. Logo - ...
(Date:1/23/2015)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ... and sale of patented biopharmaceutical medicine, modernized traditional Chinese ... today announced the business and development progress at its ... Following the September 2014 JCM application (No. 51268) for ...
(Date:1/22/2015)... 2015  BiOptix is pleased to announce the appointment of ... Chemistry and Biochemistry. Scott joins the company after previous scientific ... throughout the course of his nearly 20 year career ... a nationally recognized thought leader in the biosensor field ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... 28, 2011 Reportlinker.com announces that ... available in its catalogue: ... Care Devices Market Outlook to 2017- ... http://www.reportlinker.com/p0739469/South-and-Central-America-Diabetes-Care-Devices-Market-Outlook-to-2017--Glucose-Monitoring-and-Insulin-Delivery.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ...
... MYL ) today announced that its subsidiary Mylan ... and Drug Administration (FDA) for its Abbreviated New Drug Application ... mg (base). This product is the generic version of Abbott ... hypertension. Mylan was the first company to ...
Cached Medicine Technology:South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 2South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 3South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 4South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 5South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 6South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 7South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 8South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 9Mylan Launches First Generic Version of Teveten® Tablets 2
(Date:1/22/2015)... January 22, 2015 Joan Lunden, award-winning ... speaker at the upcoming 32nd Annual Miami Breast ... Physicians’ Education Resource®, LLC (PER®) , shares that “a ... gone undetected if she had not followed up her ...
(Date:1/22/2015)... La Jolla, Calif. (PRWEB) January 22, 2015 ... and Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen ... (CHI) for their leadership in advancing biotechnology, biomedical ... Mitchell, Bonilla and Olsen each received the “2014 ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative ... design to treat specific body parts and muscle groups. , ... easy to use patented cold therapy machine with the innovative ... and muscle injuries. IsoComforter has become the industry leader ...
(Date:1/22/2015)... Payday lending practices in four southern ... financial distress to the states that permit them, according ... Center on Race and Wealth. , While they generate ... loans at the same time substantially depress economic activity, ...
(Date:1/22/2015)... As interest in the value of spiritual support ... Rev. Eric J. Hall , president and CEO of ... be the keynote speaker on January 27 at an international ... , The conference, “Hope and Resilience: Innovative and Interdisciplinary Spiritual ...
Breaking Medicine News(10 mins):Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
... 11 The Guidebook of Sexual Medicine,was ... as the main unit for,treatment of sexual ... the thorough evaluation of biological factors (e.g., ... psychosocial factors (e.g.,presence of depression, relational conflicts, ...
... Welcome to Consumer,Reports Health News for health ... issues pertaining to the efficacy and safety,of ... health, diet and nutrition, food safety, and ... the effectiveness and affordability of,prescription drugs, and ...
... 11, 2008) The World Bank and Conservation International ... new funds, provided by the Global Environment Facility (GEF), ... threatened areas, including island ecosystems and temperate forests. , ... of all terrestrial plants and animals, as well as ...
... drugs reduce risk of major vascular events , FRIDAY, ... be considered for treatment with cholesterol-lowering statins. , That,s the ... 12 issue of The Lancet . , The British ... major vascular events in a wide range of people with ...
... offered free by LifeSpan Nutrition, SAN DIMAS, Calif., ... Family Guide To Vitamin D", which reveals,the new unfolding ... health and the health of your loved ones., ... says,achieving adequate levels of vitamin D will do more ...
... MONTREAL, Jan. 11 /PRNewswire-FirstCall/ - DRAXIS Health Inc, (TSX:,DAX) (NASDAQ: ... (TSX) to make,a Normal Course Issuer Bid (NCIB), subject to ... of the TSX., The maximum number of common shares ... such number of common shares which,represents 10% of the common ...
Cached Medicine News:Health News:A New Book on Sexual Medicine Calls Attention to 'The Couple' and Presents State-of-the Art Treatments for Sexual Dysfunction 2Health News:Consumer Reports Health News 2Health News:Consumer Reports Health News 3Health News:Consumer Reports Health News 4Health News:Global Environment partners provide additional $20 million to protect endangered habitats 2Health News:Statin Therapy Helps Diabetic Patients 2Health News:Join the Vitamin D Revolution: How to Get 30 Minutes of Daily Sunshine for Optimal Health 2Health News:DRAXIS Announces Application for Normal Course Issuer Bid 2Health News:DRAXIS Announces Application for Normal Course Issuer Bid 3Health News:DRAXIS Announces Application for Normal Course Issuer Bid 4
...
...
...
Rhoton Curettes, titanium, length 191 mm, straight....
Medicine Products: